Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald

Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock.

Verastem is on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma. Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Incyte Corporation Rising Large Players Volume in Ascending Triangle

Incyte Corporation stock has rising large players volume in an Ascending Triangle pattern. The large players volume rising while Incyte has been consolidating is a bullish pattern.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

BioDelivery Sciences Symmetrical Triangle On Rising Large Players Volume

Biodelivery Sciences is in a Symmetrical Triangle pattern on rising large players volume.

There 5 Buy ratings on Biodelivery Sciences and 1 Hold rating. The consensus price target is $4.50 which represents 52.54% upside from the current price.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Verastem Inc Price Target Raised By Cantor Fitzgerald

Verastem Inc price target was raised to $17 by Cantor Fitzgerald last week. The new $17 price target represents 330% upside from the previous close of $3.95. Cantor has a Buy rating on the stock.

Cantor Fitzgerald is respected on Wall Street but they do not have the most accurate analysts IMO. Oppenheimer Holdings Inc is a more followed analyst than Cantor Fitzgerald. It's no surprise then that I think it's more significant that on October 12, 2017, Oppenheimer reiterated their Buy rating on Verastem Inc stock and set a price target of $6 which represents an upside of 52% from the previous close. The $6 price target seems more down-to-earth and achievable than Cantor's stratospheric $17 price target.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

ContraVir Pharmaceuticals Short Covering On Maxim Price Hike

ContraVir Pharmaceuticals stock had short covering ahead of a price target hike by Maxim Group. A new $4 price target was set by analysts at Maxim Group on Thursday, October 19, 2017, which represents a 451% upside from the previous close of $0.73. Maxim has a Buy rating on ContraVir Pharmaceuticals stock.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Sell Anavex Life Sciences For a Huge 40% Win

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Sell Cancer Genetics For an Awesome 133% Win!

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Sell Portola Pharmaceuticals For a 45% Win!

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Jazz Pharmaceuticals Announces Positive Results From Phase 3 TONES 3 and TONES 4

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Teligent FDA Approves Clobetasol Propionate Gel

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.